Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.
作者信息
Schade Sebastian, Mollenhauer Brit, Trenkwalder Claudia
机构信息
Department of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany.
Paracelsus-Elena-Klinik Klinikstr. 16, 34128 Kassel Germany.
出版信息
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.
Abstract
摘要
相似文献
1
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.
2
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Acta Neurol Scand. 2019 Jul;140(1):23-31. doi: 10.1111/ane.13096. Epub 2019 Apr 22.
3
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.
4
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
J Parkinsons Dis. 2015;5(3):475-81. doi: 10.3233/JPD-150569.
5
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Neuropharmacology. 2014 Feb;77:334-41. doi: 10.1016/j.neuropharm.2013.10.014. Epub 2013 Oct 19.
6
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Br J Pharmacol. 2015 Apr;172(7):1739-52. doi: 10.1111/bph.13020. Epub 2015 Jan 20.
7
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700.
8
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.
9
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Neurol Sci. 2018 Apr;39(4):733-739. doi: 10.1007/s10072-018-3272-y. Epub 2018 Feb 13.
10
Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
Neurodegener Dis Manag. 2018 Oct;8(5):349-360. doi: 10.2217/nmt-2018-0020. Epub 2018 Jul 5.
引用本文的文献
1
Exploring the relationship between orthostatic hypotension and gait in people with Parkinson's disease.
Clin Auton Res. 2025 Sep 6. doi: 10.1007/s10286-025-01149-1.
2
Quantitative analysis of gait parameters in Parkinson's disease and the clinical significance.
Front Neurol. 2025 Aug 20;16:1527020. doi: 10.3389/fneur.2025.1527020. eCollection 2025.
3
Comparative study of autonomic dysfunction between Parkinson's disease with LRRK2, PRKN, and GBA mutations.
Front Neurol. 2025 Aug 19;16:1657824. doi: 10.3389/fneur.2025.1657824. eCollection 2025.
4
Parkinson's disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial.
NPJ Parkinsons Dis. 2025 Aug 20;11(1):249. doi: 10.1038/s41531-025-00977-2.
5
Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.
J Neural Transm (Vienna). 2025 Aug 16. doi: 10.1007/s00702-025-02999-9.
6
CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor complications.
J Neurol. 2025 Aug 13;272(9):573. doi: 10.1007/s00415-025-13325-4.
7
Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.
Brain Sci. 2025 Jun 20;15(7):666. doi: 10.3390/brainsci15070666.
8
Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools.
Age Ageing. 2025 Jul 1;54(7). doi: 10.1093/ageing/afaf197.
9
Transformer-based long-term predictor of subthalamic beta activity in Parkinson's disease.
NPJ Parkinsons Dis. 2025 Jul 12;11(1):210. doi: 10.1038/s41531-025-01011-1.
10
Rotigotine Patch is Effective for Levodopa (L-Dopa)-Induced Dyspnea: A Case Report.
Cureus. 2025 Jun 2;17(6):e85258. doi: 10.7759/cureus.85258. eCollection 2025 Jun.
本文引用的文献
1
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.
2
Safinamide: an add-on treatment for managing Parkinson's disease.
Clin Pharmacol. 2018 Apr 5;10:31-41. doi: 10.2147/CPAA.S137740. eCollection 2018.
3
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
J Parkinsons Dis. 2018;8(2):217-231. doi: 10.3233/JPD-171225.
4
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316.
5
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429.
Zotero 插件